Trial: 201711014

A Phase 1, Multicenter, Dose-escalation and Expansion Study of ARX788 as Monotherapy in Advanced Solid Tumors with HER2-expression

Phase

I (Cancer Control)

Principal Investigator

Park, Haeseong

Disease Site

Anus; Bones and Joints; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lung Cancer – Non-small Cell; Lung Cancer – Small Cell; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Sarcoma; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder; Uveal Tract Melanoma

Learn more about this study at: clinicaltrials.gov